{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:20:36Z","timestamp":1762521636221,"version":"build-2065373602"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clml.2013.11.005","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T06:30:43Z","timestamp":1384497043000},"page":"253-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ibrutinib and Indolent B-Cell Lymphomas"],"prefix":"10.1016","volume":"14","author":[{"given":"Akintunde","family":"Akinleye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Furqan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwaseyi","family":"Adekunle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.11.005_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/asheducation.V2000.1.166.166","article-title":"Managing indolent lymphomas in relapse: working our way through a plethora of options","volume":"2000","author":"Cabanillas","year":"2000","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2013.11.005_bib2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.005_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/asheducation-2005.1.299","article-title":"Hematopathology approaches to diagnosis and prognosis of indolent B-cell lymphomas","volume":"2005","author":"Gascoyne","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2013.11.005_bib4","first-page":"71","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2013.11.005_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2012.09.004","article-title":"Management of indolent lymphoma: where are we now and where are we going","volume":"26","author":"Lunning","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2013.11.005_bib6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.005_bib7","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.005_bib8","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1182\/blood-2008-02-139139","article-title":"Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in\u00a0apoptotic mechanisms in B-chronic lymphocytic leukemia","volume":"112","author":"Trentin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.005_bib9","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.005_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"K\u00fcppers","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2013.11.005_bib11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/jlb.65.3.286","article-title":"Functions of Bruton's tyrosine kinase in mast and B cells","volume":"65","author":"Kawakami","year":"1999","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.clml.2013.11.005_bib12","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1074\/jbc.274.16.10983","article-title":"Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells","volume":"274","author":"V\u00e1rnai","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.11.005_bib13","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1128\/MCB.02009-05","article-title":"Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I","volume":"26","author":"Rajaiya","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2013.11.005_bib14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/ni1001-939","article-title":"Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein","volume":"2","author":"Liu","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2013.11.005_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0014-5793(94)00783-7","article-title":"Tec homology (TH) adjacent to the PH domain","volume":"350","author":"Vihinen","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.clml.2013.11.005_bib16","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1093\/emboj\/20.20.5692","article-title":"PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization","volume":"20","author":"Kang","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2013.11.005_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1570-9639(02)00524-1","article-title":"Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases","volume":"1645","author":"Nore","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2013.11.005_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1074-7613(00)80417-3","article-title":"Regulation of Btk function by a major autophosphorylation site within the SH3 domain","volume":"4","author":"Park","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2013.11.005_bib19","doi-asserted-by":"crossref","first-page":"40614","DOI":"10.1074\/jbc.M006952200","article-title":"Nucleocytoplasmic shuttling of Bruton's tyrosine kinase","volume":"275","author":"Mohamed","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.11.005_bib20","first-page":"D917","article-title":"Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA)","volume":"5","author":"Vihinen","year":"2000","journal-title":"Front Biosci"},{"key":"10.1016\/j.clml.2013.11.005_bib21","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1002\/eji.1830231210","article-title":"The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages","volume":"23","author":"de Weers","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clml.2013.11.005_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clml.2013.11.005_bib23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/smim.1998.0123","article-title":"Btk function in B cell development and response","volume":"10","author":"Satterthwaite","year":"1998","journal-title":"Semin Immunol"},{"key":"10.1016\/j.clml.2013.11.005_bib24","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.4049\/jimmunol.176.6.3635","article-title":"Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production","volume":"176","author":"Horwood","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2013.11.005_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.182.1.329","article-title":"Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells","volume":"182","author":"Sharma","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2013.11.005_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1073\/pnas.94.2.604","article-title":"BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement","volume":"94","author":"Yang","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clml.2013.11.005_bib27","doi-asserted-by":"crossref","first-page":"47982","DOI":"10.1074\/jbc.M107577200","article-title":"Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme function in B-cell signaling","volume":"276","author":"Rodriguez","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.11.005_bib28","doi-asserted-by":"crossref","first-page":"14180","DOI":"10.1073\/pnas.0405878101","article-title":"A\u00a0phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation","volume":"101","author":"Guo","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clml.2013.11.005_bib29","doi-asserted-by":"crossref","first-page":"38595","DOI":"10.1074\/jbc.M103675200","article-title":"Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B\u00a0cell antigen receptor-coupled calcium signaling","volume":"276","author":"Watanabe","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.11.005_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/bst0320113","article-title":"B-cell antigen receptor activates transcription factors NFAT (nuclear factor of activated T-cells) and NF-kappaB (nuclear factor kappaB) via a mechanism that involves diacylglycerol","volume":"32","author":"Antony","year":"2004","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.clml.2013.11.005_bib31","doi-asserted-by":"crossref","first-page":"36953","DOI":"10.1074\/jbc.M707682200","article-title":"Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase","volume":"282","author":"Doyle","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.11.005_bib32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0006-2952(98)00122-1","article-title":"Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis","volume":"56","author":"Uckun","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clml.2013.11.005_bib33","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1073\/pnas.96.11.6341","article-title":"Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein","volume":"96","author":"Yamadori","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clml.2013.11.005_bib34","doi-asserted-by":"crossref","first-page":"18201","DOI":"10.1074\/jbc.M603090200","article-title":"Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1","volume":"281","author":"Yu","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.11.005_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.clml.2013.11.005_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.clml.2013.11.005_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20030615","article-title":"Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells","volume":"198","author":"Kersseboom","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2013.11.005_bib38","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1074\/jbc.274.3.1646","article-title":"Bruton's tyrosine kinase as an inhibitor of the Fas\/CD95 death-inducing signaling complex","volume":"274","author":"Vassilev","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.11.005_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.clml.2013.11.005_bib40","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.4049\/jimmunol.176.10.5715","article-title":"Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma","volume":"176","author":"Gururajan","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2013.11.005_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clml.2013.11.005_bib42","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/1042819031000067576","article-title":"Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia","volume":"44","author":"Goodman","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.11.005_bib43","first-page":"71","article-title":"Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia","volume":"3","author":"Kil","year":"2013","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.clml.2013.11.005_bib44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cgh.2007.08.019","article-title":"Multiple colorectal neoplasms in X-linked agammaglobulinemia","volume":"6","author":"Brosens","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2013.11.005_bib45","doi-asserted-by":"crossref","first-page":"R243","DOI":"10.1186\/ar4086","article-title":"Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus","volume":"14","author":"Hutcheson","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clml.2013.11.005_bib46","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","article-title":"Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765)","volume":"54","author":"Burger","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.11.005_bib47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/ar3439","article-title":"More than just B-cell inhibition","volume":"13","author":"Ruderman","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clml.2013.11.005_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-6-36","article-title":"Novel agents for chronic lymphocytic leukemia","volume":"6","author":"Wu","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2013.11.005_bib49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.clml.2013.11.005_bib50","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clml.2013.11.005_bib51","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2013.11.005_bib52","article-title":"Combination of ACY1215, a selective histone deacetylase 6 (HDAC6) inhibitor with the bruton tyrosine kinase (BTK) inhibitor, ibrutinib, represents a novel therapeutic strategy in mantle cell lymphoma (MCL)","volume":"120","author":"Sahakian","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.11.005_bib53","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in\u00a0vitro and in\u00a0vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.005_bib54","article-title":"BTK Inhibition Targets in\u00a0Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity","volume":"120","author":"Wang","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.11.005_bib55","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.005_bib56","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.005_bib57","article-title":"A\u00a0phase I dose escalation study of the Btk inhibitor PCI-32765 in relapsed and refractory B cell non-Hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay","volume":"114","author":"PollyeaD","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.005_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.11.005_bib59","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2013.11.005_bib60","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/1078-0432.CCR-10-0570","article-title":"U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab","volume":"16","author":"Lemery","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.11.005_bib61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.clml.2013.11.005_bib62","volume":"31","author":"Byrd","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.11.005_bib63","volume":"120","author":"Byrd","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"suppl","key":"10.1016\/j.clml.2013.11.005_bib64","article-title":"Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL\/SLL (RESONATE-2, PCYC-1115-CA)","volume":"31","author":"Burger","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2013.11.005_bib65","article-title":"Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL)","volume":"31","author":"Chang","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.11.005_bib66","article-title":"The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients","volume":"120","author":"Burger","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.11.005_bib67","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.11.005_bib68","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL Study Group","volume":"90","author":"Bergmann","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.11.005_bib69","article-title":"Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine\/rituximab (BR) in patients with relapsed\/refractory chronic lymphocytic leukemia: Interim results of a phase Ib\/II study","author":"Brown","year":"2012","journal-title":"EHA Meet"},{"key":"10.1016\/j.clml.2013.11.005_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6508","article-title":"A\u00a0phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases","author":"Jaglowski","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.11.005_bib71","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma","volume":"120","author":"Fowler","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"suppl","key":"10.1016\/j.clml.2013.11.005_bib72","article-title":"An open-label phase II study of ibrutinib in\u00a0patients with refractory follicular lymphoma","volume":"31","author":"Salles","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.11.005_bib73","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.11.005_bib74","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.11.005_bib75","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with\u00a0mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.11.005_bib76","article-title":"A\u00a0phase I trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non-Hodgkin's lymphoma (NHL)","volume":"120","author":"Blum","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"suppl","key":"10.1016\/j.clml.2013.11.005_bib77","article-title":"A\u00a0phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL)","volume":"31","author":"Wang","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2013.11.005_bib78","article-title":"Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL)","volume":"31","author":"Younes","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:42Z","timestamp":1761870282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013004709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S2152265013004709"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.11.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib and Indolent B-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}